Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  World Journal of Hepatology

• Publication date

  2015-04-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.4254/wjh.v7.i5.725PMID 25914773PMCID PMC4404378
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

  2015cited by this paper
• Clinical course of infection and viral tissue tropism of hepatitis C virus–like nonprimate hepaciviruses in horses

  2015cited by this paper
• Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

  2015cited by this paper
• Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

  2015cited by this paper
• Protective Immunity Against Hepatitis C: Many Shades of Gray

  2014cited by this paper
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

  2014cited by this paper
• Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?

  2014cited by this paper
• Structure of the Core Ectodomain of the Hepatitis C Virus Envelope Glycoprotein 2

  2014cited by this paper
• Recurrent HCV after liver transplantation—mechanisms, assessment and therapy

  2014cited by this paper
• Resistance to hepatitis C virus protease inhibitors.

  2014cited by this paper
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  2014cited by this paper
• Update on hepatitis C virus resistance to direct-acting antiviral agents.

  2014cited by this paper
• A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

  2014cited by this paper
• Development and function of human innate immune cells in a humanized mouse model

  2014cited by this paper
• Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes

  2014cited by this paper
• The past, present and future of neutralizing antibodies for hepatitis C virus

  2014cited by this paper
• Global Distribution and Prevalence of Hepatitis C Virus Genotypes

  2014cited by this paper
• Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver

  2014cited by this paper
• Daclatasvir + Asunaprevir: First Global Approval

  2014cited by this paper
• New hepatitis C therapies: the toolbox, strategies, and challenges.

  2014cited by this paper
• Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

  2014cited by this paper
• Trace amounts of sporadically reappearing HCV RNA can cause infection.

  2014cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

  2014cited by this paper
• All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

  2014cited by this paper
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

  2014cited by this paper
• ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

  2014cited by this paper
• A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity

  2014cited by this paper
• Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

  2014cited by this paper
• Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys.

  2014cited by this paper
• Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity

  2014cited by this paper
• Hepatitis C virus clearance correlates with HLA‐DR expression on proliferating CD8+ T cells in immune‐primed chimpanzees

  2014cited by this paper
• Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

  2014cited by this paper
• Completion of the entire hepatitis C virus life-cycle in genetically humanized mice

  2013cited by this paper
• Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

  2013cited by this paper
• Sofosbuvir for previously untreated chronic hepatitis C infection.

  2013cited by this paper
• Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence

  2013cited by this paper
• Regulation of hepatic innate immunity by hepatitis C virus

  2013cited by this paper
• Poliovirus vaccination options for achieving eradication and securing the endgame.

  2013cited by this paper
• Simultaneous detection of hepatitis C virus antigen and antibodies in dried blood spots.

  2013cited by this paper
• The ins and outs of hepatitis C virus entry and assembly

  2013cited by this paper
• Hepatitis C Virus E2 Envelope Glycoprotein Core Structure

  2013cited by this paper
• Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells

  2013cited by this paper
• Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource

  2013cited by this paper
• Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.

  2013cited by this paper
• Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

  2013cited by this paper
• Current progress in development of hepatitis C virus vaccines

  2013cited by this paper
• Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

  2013cited by this paper
• Sustained virologic response: Is this equivalent to cure of chronic hepatitis C?

  2013cited by this paper
• NS5A inhibitors in the treatment of hepatitis C.

  2013cited by this paper
• Epidemiology and natural history of HCV infection

  2013cited by this paper
• Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention.

  2012cited by this paper
• Factors that predict response of patients with hepatitis C virus infection to boceprevir.

  2012cited by this paper
• Current advances in humanized mouse models

  2012cited by this paper
• Awareness of infection, knowledge of hepatitis C, and medical follow‐up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001‐2008

  2012cited by this paper
• Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C

  2012cited by this paper
• Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution

  2012cited by this paper
• IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

  2012cited by this paper
• Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.

  2012cited by this paper
• Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

  2012cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• From smallpox eradication to the future of global health: innovations, application and lessons for future eradication and control initiatives.

  2011cited by this paper
• Interferon lambdas: the next cytokine storm

  2011cited by this paper
• A genetically humanized mouse model for hepatitis C virus infection

  2011cited by this paper
• Host genetics in immune-mediated hepatitis C virus clearance.

  2011cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2011cited by this paper
• Experimental models to study the immunobiology of hepatitis C virus.

  2011cited by this paper
• Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.

  2011cited by this paper
• Boceprevir for previously treated chronic HCV genotype 1 infection.

  2011cited by this paper
• Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.

  2011cited by this paper
• Telaprevir for retreatment of HCV infection.

  2011cited by this paper
• HCV Routes of Transmission: What Goes Around Comes Around

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• New insights into the HCV quasispecies and compartmentalization.

  2011cited by this paper
• Manifestations of chronic hepatitis C virus infection beyond the liver.

  2010cited by this paper
• Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

  2010cited by this paper
• Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.

  2010cited by this paper
• Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

  2010cited by this paper
• Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

  2009cited by this paper
• Diagnosis, management, and treatment of hepatitis C: An update

  2009cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.

  2008cited by this paper
• Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

  2008cited by this paper
• Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.

  2007cited by this paper
• Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

  2007cited by this paper
• The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

  2006cited by this paper
• A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

  2006cited by this paper
• Treating viral hepatitis C: efficacy, side effects, and complications

  2006cited by this paper
• Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C

  2005cited by this paper
• Robust hepatitis C virus infection in vitro.

  2005cited by this paper
• Complete Replication of Hepatitis C Virus in Cell Culture

  2005cited by this paper
• Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C

  2005cited by this paper
• Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

  2005cited by this paper
• Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

  2005cited by this paper

• Novel Pyrazino[1,2-a]indole-1,3(2H,4H)-dione Derivatives Targeting the Replication of Flaviviridae Viruses: Structural and Mechanistic Insights

  2024cites this paper
• Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV.

  2023cites this paper
• Recent Advancements in NS5B Inhibitors (2011-2021): Structural Insights, SAR Studies and Clinical Status

  2023cites this paper
• Synthetic approaches and application of clinically approved small-molecule drugs to treat hepatitis.

  2023cites this paper
• Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus.

  2022cites this paper
• Prevalence and determinants of Hepatitis C Virus Infection and Genotypes in Chronic Hemodialysis Patients in Kinshasa Prévalence

  2022cites this paper
• Revolution in the diagnosis and management of hepatitis C virus infection in current era

  2022cites this paper
• Uridine-Derived 4-Aminophenyl 1-Thioglucosides: DFT Optimized FMO, ADME, and Antiviral Activities Study

  2022cites this paper
• The role of Th17 cells in viral infections.

  2021cites this paper
• Hepatitis C Virus Infection and Genotypes in Chronic Hemodialysis Patients in Kinshasa: Prevalence and Risk Factors

  2021influential citation
• Changing Etiology and Epidemiology of Human Liver Cancer

  2021cites this paper
• Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection.

  2021cites this paper
• Thiosemicarbazides: Updates on antivirals strategy.

  2020cites this paper
• Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system

  2020cites this paper
• Novel Models to Identify Census Tracts for Hepatitis C Screening Interventions

  2020cites this paper
• HCV resistance compartmentalization within tumoral and non‐tumoral liver in transplanted patients with hepatocellular carcinoma

  2019cites this paper
• HCV Coinfection in a Cohort of HIV Pregnant Women

  2019cites this paper
• Highlight Article: Environmental health in the biology century: Transitions from population to personalized prevention

  2019cites this paper
• Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis

  2019cites this paper
• Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species.

  2019cites this paper
• HCV Chronicity: Is True Cure Truly Rare? Long-Term Follow-Up in Two HCV Patients

  2019cites this paper
• Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl 1-Thioglycosides, as Potential Antiviral Compounds

  2018cites this paper
• Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population

  2018cites this paper
• Treatment history: Factors that affect the outcome of hepatitis C virus treatment with interferon-alpha 2a/b and ribavirin

  2018cites this paper
• Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars

  2018cites this paper
• Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5

  2018cites this paper
• Serum IL-12p70 and TLR 7 gene expression in Egyptian patients infected with HCV and treated with Sofosbuvir, Ribavirin and/or Pegylated interferon

  2017cites this paper
• Novel nucleoside analogues targeting HCV replication through an NS5A‐dependent inhibition mechanism

  2017cites this paper
• Oxidative Stress and Immune Responses During Hepatitis C Virus Infection in Tupaia belangeri

  2017cites this paper
• Role of TLRs and IL‐6 in the outcome of chronic hepatitis C treatment in Tunisian population

  2017cites this paper
• Innate and Adaptive Immune Responses in Chronic HCV Infection.

  2017cites this paper
• From in-silico immunogenicity verification to in vitro expression of recombinant Core-NS3 fusion protein of HCV.

  2017cites this paper
• Economic study of the value of expanding HCV treatment capacity in Germany

  2017cites this paper
• Immune response of Th17‐associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection

  2017cites this paper
• Personalized Medicine for Hepatitis C Virus

  2017cites this paper
• Étude des réponses humorales chez la femme enceinte infectée par le virus de l’hépatite C : cytotoxicité dépendante des anticorps (ADCC) et réponses neutralisantes

  2017cites this paper
• Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C

  2017cites this paper
• Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma

  2017cites this paper
• Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry

  2017cites this paper
• IFN-lambda therapy: current status and future perspectives.

  2016cites this paper
• Conception et synthèse de molécules à visée anti-infectieuse selon deux stratégies : le criblage à haut débit et l’approche par fragments

  2016cites this paper
• Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4

  2016cites this paper
• The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy

  2016cites this paper
• Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression.

  2016cites this paper
• Review article: treatment as prevention – targeting people who inject drugs as a pathway towards hepatitis C eradication

  2016cites this paper
• Hepatitis C virus‐cross‐reactive TCR gene‐modified T cells: a model for immunotherapy against diseases with genomic instability

  2016cites this paper
• Using an Old Drug to Target a New Drug Site: Application of Disulfiram to Target the Zn-Site in HCV NS5A Protein.

  2016cites this paper
• Racial diversity in mortality and morbidity in urban patients with hepatitis C

  2016cites this paper
• Bicyclic octahydrocyclohepta[b]pyrrol-4(1H)one derivatives as novel selective anti-hepatitis C virus agents.

  2016cites this paper
• Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications

  2015cites this paper
• Epidemiology of hepatitis C virus in Iran.

  2015cites this paper
• Geneticin Stabilizes the Open Conformation of the 5′ Region of Hepatitis C Virus RNA and Inhibits Viral Replication

  2015cites this paper
• Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance

  2015cites this paper
• MEDICAL REVIEW JOURNAL OF THE SOCIETY OF PHYSICIANS OF VOJVODINA OF THE MEDICAL SOCIETY OF SERBIA

  2013cites this paper
• Prevalence and determinants of Hepatitis C Virus Infection and Genotypes in Chronic in

  year unknowninfluential citation